Navigation Links
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Date:10/17/2007

BOULDER, Colo., Oct. 17 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.

Approximately 30,000 patients in the US and 32,000 patients in the EU will be diagnosed with SCLC this year. "The treatment of small cell lung cancer is extremely challenging, given the limited therapeutic options available," said Mark A. Socinski, Associate Professor of Medicine, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, and a principal investigator in the Phase 3 study. "Preliminary data suggest that amrubicin could represent a significant improvement in the treatment of small cell lung cancer, for which there have been no major medical advances in more than 20 years."

The study compares amrubicin and topotecan in second-line treatment of SCLC patients with sensitive or refractory disease. Sensitive disease is defined as response to first-line platinum-based therapy, with subsequent progression 90 days or more after completion of therapy. Refractory disease is defined as no objective response or progressive disease within 90 days of completion of therapy. Study participants are randomized in a 2:1 ratio to receive either IV amrubicin (40mg/m2 daily for 3 days) or topotecan (1.5 mg/m2 daily for 5 days), both starti
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
10. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
11. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... issuance of an aggregate of 30,000 stock options to ... of 120,500 stock options to employees and consultants of ... years and will be exercisable for a period of ... stock option. About Covalon Covalon Technologies ...
(Date:3/27/2015)... - Medicure Inc. (the "Company") (TSXV:MPH, OTCQB:MCUJF) announces today ... of an aggregate of 236,070 options to certain directors, ... Company pursuant to the Company,s Stock Option Plan. Of ... tenth anniversary of the date of grant, 5,000 are ... date of grant and 50,000 are set to expire ...
(Date:3/27/2015)... , March 27, 2015  Holographic Optical Technologies of ... field of holographic medical imaging, is entering the world ... campaign. Launching on April 20 th , 2015, the ... Pro. The 8-inch and 22-inch displays will allow consumers ... the first time. In addition to the two displays, ...
Breaking Medicine Technology:Covalon Announces Issuance of Stock Options 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... 28, 2011 Shire plc , (LSE: SHP, Nasdaq: ... announced that the US Food and Drug Administration (FDA) approved ... as adjunctive therapy to stimulants for the treatment of attention ... to 17 as part of a total treatment program. The ...
... Feb. 28, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... preliminary clinical data from its Phase 1 trial (SB-728-902). ... subjects who are currently on highly active antiretroviral therapy ... CD4+ T-cell counts.  The study is designed to evaluate ...
Cached Medicine Technology:FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 2FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 3FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 4FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 5FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 6Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 2Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 3Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 4Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 5Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 6
(Date:3/28/2015)... California (PRWEB) March 28, 2015 Designers ... a new overlay entitled Scratches 5K from Pixel Film ... scratch effects to any media inside Final Cut Pro ... “StoryBoard Corporate saves time and is an effective tool ... using FCPX Overlay Scratches 5K's intuitive grunge overlays. Simply ...
(Date:3/27/2015)... The Monogamy Method - ... Sanderson and Jason Rogers has just been released to ... The commotion surrounding the course's launch has caught the ... an in-depth review of the new program. , "Many ... their lives suddenly start pulling away or expressing interest ...
(Date:3/27/2015)... First Choice Emergency Room opened ... is located 12665 W Lake Houston Pkwy, Houston, Texas and ... I look forward to delivering the highest quality emergency medical ... Director of First Choice Emergency Room Summerwood. , ... donation to Summer Creek High School at First Choice Emergency ...
(Date:3/27/2015)... March 27, 2015 Ticket Down is a reputable ... in 2015. After a phenomenal and highly successful live tour ... be going out on tour again in 2015 and they will ... underway on April 29th in New York City at the cozy ... Comerica Theatre on May 10th. , Fans of the hit show ...
(Date:3/27/2015)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) March ... and current President of DrugDev SiteStart Melissa (Liss) Easy ... Under 40. , The 40 Under 40 list ... of age for their professional accomplishments and community involvement. ... and profiled in a special supplement of the Philadelphia ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2
... Britain, women admitted in hospital wards are facing inconvenience and ... to rest comfortably as they fear sexual assault. ... have been calling them complaining of inconvenience and invasion of ... instance, a woman in her 70s was totally upset and ...
... made this summer when the U.S. Food and Drug ... cancer//. The vaccine was given the green light for ... against human papillomavirus (HPV), a sexually transmitted virus that ... for a cancer ever developed,” said Phyllis Greenberger, president ...
... that hospitals need to spruce up with infrastructure that ... //patients requiring emergency care. There appears to be immense ... be addressed without delay. , ,Dr Peter Grant, ... "Emergency departments and primary care providers must prepare for ...
... government has issued a directive to the provincial livestock authorities ... //to prevent potential bird flu that had left an indelible ... ,Yukol Limlamthong, the person at the helm at the Department ... up following the recent deluge in the central provinces. Thailand ...
... that majority of Australians actually know very little about lymphomas. ... is termed as lymphomas. Its the lymphatic system in the ... aids to fight disease. ,Data reveals that it’s ... cervical or ovarian cancer .Survey shows that more Australians die ...
... by researchers from the Royal Devon and Exeter Hospital postulates ... born short. //Mothers seem to determine how plump babies finally ... the researchers say that results derived so far, clearly point ... of fat fathers, however, did not seem to be on ...
Cached Medicine News:Health News:Triumphs and Hurdles for the New HPV Vaccine 2Health News:Triumphs and Hurdles for the New HPV Vaccine 3
Designed by a neonatalogist to reduce the number of steps required to suction meconium from the infants trachea when seconds count. Meconium suction system optimizes patient and provider safety....
... KIMBERLY-CLARK BALLARD Neonatal ... Elbow is designed for ... of elbow design provide ... lavage/irrigation port and locking ...
KIMBERLY-CLARK BALLARD Neonatal and Pediatric TRACH CARE Y features lavage/irrigation port and locking thumb port. Multiple French sizes and packaging configurations. Gamma sterilized....
... PVC siliconized. Stainless steel spiral reinforced. X-ray opaque ... use. Adjustable Flange: The flange can be adjusted ... of the cervical soft tissue. The lock ring ... connected to the shaft. Maximum Patient Comfort: The ...
Medicine Products: